Silica as a Flow Agent: How It Improves Powder Flowability

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Top Fumed Silica Manufacturers: Global Leaders and Emerging Suppliers (2026)
  • Keywords: silicon dioxide formula
  • Published: 2026-11-20 04:23:30
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals

Denka Spherical Silica: Product Overview, Specifications and Alternatives

Silicon Dioxide in Supplements: Purpose, Safety and Dosage Limits
2. Effect of the Physicochemical Properties
Silica Market Size 2026: Global Value, Growth Rate and Key Segments
The potential of MSNs may also be utilized well in the case of polypills. In this case, all drugs must be dissolved in the solvent. After that, the carriers must be loaded with this complex solution, employing one of the already mentioned drug loading techniques. This can be followed by tableting nanocarriers. This approach can be really beneficial in the treatment of hypertension, where combination therapy is most often used. Patient compliance could also be improved with the production of such a polypill, since taking one pill rather than multiple pills may be simpler for the combined treatment of high blood pressure [ 99 ].
Silica Market Trends 2026: Demand Drivers, Technologies and Regional Outlook
80. Ajit J. Nanoparticles in Drug Delivery. Prem. J. Sci. 2025;1:100048. doi: 10.70389/PJS.100048. [ DOI ] [ Google Scholar ]
Aerosil R972: Specifications, Hydrophobic Properties and Equivalent Grades
Ho et al. employed the Multiple-Path Particle Dosimetry (MPPD) model for aerosolization and determination of lung deposition of silver nanoparticles, which method may be broadened to other materials like mesoporous silica nanoparticles [ 87 ]. It suggests particle size (mean 18 nm), density, and generation approach as principal elements that determine aerosolization efficiency and inhaled dose. Simulations of airflow, diffusion, sedimentation, and impact through airway generations yield comparable alveolar deposition fractions for particles less than 100 nm in humans and rats. With the addition of species-specific parameters, such as respiratory rate, lung surface region, tidal volume, and finished with possible lobar- and airway-level analysis, the MPPD model makes realistic regional retention predictions. Given that mesoporous silica nanoparticles are of similar size and physicochemical properties, the same methodology can estimate their aerosolization and lung deposition. In summary, the MPPD model is a handy tool in the assessment of inhalation danger and in guiding the formulation of safer nanomaterials [ 87 ]. In another study, Ali et al. applied the MPPD model to simulate aerosolization and lung deposition of mesoporous silica nanoparticles [ 88 ]. Pre-characterized MSNs with pre-specified aerodynamic diameters were initially assessed through scanning mobility particle sizing to yield accurate size-distribution inputs. Asymmetric mouse airway geometry and physiological parameters such as respiratory rate, lung volume, and airflow were used in simulations that were approximated to provide a total lung deposition of about 45%, of which 37% was in the head, 27% in the tracheobronchial, and 36% in the pulmonary (alveolar) region. These predictions are in reasonable agreement with earlier in vivo findings, validating the model. MPPD analysis also indicated that smaller MSNs exhibit more alveolar deposition, with the larger particles being better in the upper airways. Through linking aerosolization efficiency (via size distribution and concentration) and regional deposition, this modeling approach orients optimization of nanoparticle size and generation techniques toward maximizing targeted lung delivery [ 88 ]. To achieve easier production of aerosols, the surface of nanoparticles is often provided with a polymer coating, thereby stabilizing their distribution and increasing dispersibility [ 56 ]. By lowering the particle size, deeper lung areas can be reached [ 25 ]. Particles smaller than 1 µm are capable of accumulating in the alveoli, but the ideal size range to achieve maximum efficiency is in the 200-500 nm range [ 25 ]. Nevertheless, another review cited that particle size in the range of 50-200 nm is ideal for maximizing drug localization by inhalation [ 89 ]. It has also been recommended that the perfect diameter is approximately 500 nm for phagocytosis by alveolar macrophages [ 89 ]. Li et al. nebulized PEI-PEG-coated MSNs (50 nm particle size) by standard nebulizers without compromising their structure, while keeping particles in their individual form within the water droplets [ 90 ]. The aerosol supplies convenient delivery of MSNs to all areas of the respiratory tract - nasal, tracheobronchial, and pulmonary - and they persist for a week following inhalation, mostly within alveolar macrophages. It offers intracellular targeted delivery of lung diseases without passing through the gastrointestinal and first-pass metabolism. In spite of decreased deep lung deposition in mice under nasal breathing, exposure is comparable to that of humans with inhalation. Toxicity tests revealed no tissue damage or inflammation, further supporting MSN inhalation as a safe and effective method for vast treatment of pulmonary diseases, feasible for clinical translation [ 90 ]. A study investigated the effect of surface chemistry on drug loading capacity, release kinetics, and antibiotic activity in pulmonary infections on S. aureus bacterial cultures [ 18 ]. The model drugs were isoniazid, rifampicin, and vancomycin. Remarkable absorption ability was observed only with thiol (-SH) grafted carriers for all the tested drugs [ 18 ]. The in vitro drug release study showed sustained, but limited release: the cumulative release of rifampicin was 78.5% after 12 days, estimated by antibiogram [ 18 ]. Interestingly, the MIC values of the MSN-drug complex were higher for the free drug, probably due to the delayed and incomplete release from the pores [ 18 ]. Wang et al. developed a polydopamine-coated MSN formulation co-loaded with Ziyuglycoside I and Oseltamivir for the treatment of viral pneumonia. Interestingly, in vitro and in vivo studies have demonstrated that this carrier provided immediate release of Oseltamivir (allows quick virus killing) but prolonged release of Ziyuglycoside I (cuts down the inflammatory response for a longer period) [ 62 ].

What Is Modified Silica? Surface Modification Methods and Performance Benefits

What is silica (SiO₂)?

Denka spherical silica

What is the difference between fumed silica and precipitated silica?

silica thickening agent 7. Vallet-Regi M., Rámila A., Del Real R.P., Pérez-Pariente J. A new property of MCM-41: Drug delivery system. Chem. Mater. 2001;13:308-311. doi: 10.1021/cm0011559. [ DOI ] [ Google Scholar ]

What drives silica raw material prices?

fused silica sand 63. Radhakrishnan D., Patel V., Mohanan S., Ramadass K., Karakoti A., Vinu A. Folic acid functionalised mesoporous core-shell silica nanoparticles loaded with carboplatin for lung cancer therapy. Microporous Mesoporous Mater. 2023;360:112708. doi: 10.1016/j.micromeso.2023.112708. [ DOI ] [ Google Scholar ]

Cite this article: Silica Raw Materials News. "Silica MSDS: How to Read It and What Safety Information to Check ." Published 2026-11-20 04:23:30. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.